---
title: "ZIVO BIOSCIENCE INC | 10-Q: FY2025 Q1 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/240445578.md"
datetime: "2025-05-15T20:12:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/240445578.md)
  - [en](https://longbridge.com/en/news/240445578.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/240445578.md)
generator: "portal-rs"
---

# ZIVO BIOSCIENCE INC | 10-Q: FY2025 Q1 Revenue: USD 0

Revenue: As of FY2025 Q1, the actual value is USD 0.

EPS: As of FY2025 Q1, the actual value is USD -1.12.

EBIT: As of FY2025 Q1, the actual value is USD -4.209 M.

### Segment Revenue

-   **Total Revenues**: For the three months ended March 31, 2025, Zivo Bioscience, Inc. recorded no revenue, compared to $35,720 for the same period in 2024, due to no product orders from the exclusive distributor.

### Operational Metrics

-   **Net Loss**: The net loss for the three months ended March 31, 2025, was $4,211,188, compared to $1,278,486 for the same period in 2024.
-   **General and Administrative Expenses**: Increased to $1,439,552 in 2025 from $975,574 in 2024, primarily due to higher professional fees.
-   **Research and Development Expenses**: Increased significantly to $2,769,236 in 2025 from $312,767 in 2024, largely due to costs associated with extinguishing Participation Agreements.

### Cash Flow

-   **Operating Cash Flow**: Net cash used in operating activities was - $1,430,238 for the three months ended March 31, 2025, compared to - $1,699,118 for the same period in 2024.
-   **Financing Activities**: Generated $404,985 in 2025, a decrease from $1,563,379 in 2024, due to the absence of funds raised through sales of common stock in 2025.

### Future Outlook and Strategy

-   **Core Business Focus**: Zivo Bioscience, Inc. plans to continue developing bioactive compounds from its proprietary algal culture, targeting diseases such as poultry coccidiosis and bovine mastitis, and seeks strategic partners for late-stage development and commercialization.
-   **Non-Core Business**: The company is exploring additional indications such as avian influenza and canine joint health, pending additional funding.
-   **Funding Requirements**: The company acknowledges substantial doubt about its ability to continue as a going concern and requires approximately $5 million in cash over the next 12 months to fund basic operations, excluding R&D initiatives.

### Related Stocks

- [ZIVOW.US](https://longbridge.com/en/quote/ZIVOW.US.md)

## Related News & Research

- [Balanced Risk/Reward Keeps Workday at Hold as Brent Thill Raises Price Target from $205 to $225 on Potential Silver Lake Takeout Upside](https://longbridge.com/en/news/296711228.md)
- [3,759 Shares in Ferrari N.V. $RACE Acquired by X Square Capital LLC](https://longbridge.com/en/news/296700358.md)
- [Korea Investment CORP Increases Stock Position in L3Harris Technologies Inc $LHX](https://longbridge.com/en/news/296698330.md)
- [Johnson & Johnson $JNJ Position Reduced by Oppenheimer Asset Management Inc.](https://longbridge.com/en/news/296697035.md)
- [Danske Bank A S Invests $252.05 Million in Bank of America Corporation $BAC](https://longbridge.com/en/news/296695181.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**